Namely, it is essential to differentiate between IDH-mutant and IDHwt astrocytoma, given the vastly different clinical behavior, and the potential for using FDA approved IDH inhibitors in the near future. The gene discussed is IDH2; the disease is astrocytoma (excluding glioblastoma).